Adage Capital Partners GP L.L.C. Acquires New Position in VYNE Therapeutics Inc. (NASDAQ:VYNE)

Adage Capital Partners GP L.L.C. bought a new position in shares of VYNE Therapeutics Inc. (NASDAQ:VYNE) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm bought 154,134 shares of the company’s stock, valued at approximately $516,000. Adage Capital Partners GP L.L.C. owned about 1.04% of VYNE Therapeutics as of its most recent SEC filing.

Separately, XTX Topco Ltd bought a new position in VYNE Therapeutics during the fourth quarter worth $70,000. Hedge funds and other institutional investors own 83.78% of the company’s stock.

VYNE Therapeutics Trading Down 2.1 %

Shares of VYNE Therapeutics stock opened at $1.41 on Wednesday. The stock has a market capitalization of $21.45 million, a price-to-earnings ratio of -1.64 and a beta of 1.37. VYNE Therapeutics Inc. has a twelve month low of $1.28 and a twelve month high of $4.30. The business’s 50 day simple moving average is $1.88 and its 200-day simple moving average is $2.46.

VYNE Therapeutics (NASDAQ:VYNE) last posted its earnings results on Thursday, March 6th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.03. The company had revenue of $0.08 million for the quarter, compared to analysts’ expectations of $0.14 million. VYNE Therapeutics had a negative return on equity of 43.73% and a negative net margin of 6,896.55%. Sell-side analysts predict that VYNE Therapeutics Inc. will post -0.97 earnings per share for the current year.

Analysts Set New Price Targets

Separately, HC Wainwright lowered their target price on shares of VYNE Therapeutics from $5.75 to $4.50 and set a “buy” rating for the company in a research note on Friday, April 25th.

About VYNE Therapeutics

VYNE Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.